NRIX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Nurix Therapeutics Inc (NRIX) does not present a strong buy opportunity for a long-term beginner investor at this time. While the stock has some positive technical indicators and a recent price increase, the lack of significant trading signals, neutral sentiment from hedge funds and insiders, and no recent news or congress trading data suggest limited immediate upside potential. Additionally, while analysts have raised price targets, the stock's financial performance and valuation data are unavailable, making it difficult to fully assess its growth potential.
The technical indicators for NRIX show a bullish trend with MACD positively expanding, RSI at 72.529 in the neutral zone, and moving averages (SMA_5 > SMA_20 > SMA_200) indicating upward momentum. The stock is trading above its pivot level of 16.514, with resistance levels at 18.298 and 19.4.
Analysts have raised price targets recently, with Baird increasing its target to $33, reflecting a partnership with Roche and continued clinical performance. Technical indicators suggest a bullish trend.
No recent news or significant trading trends from hedge funds or insiders. Financial performance data is unavailable, and there are no recent congress trading activities. Additionally, the stock's implied volatility percentile is relatively low at 29.76, suggesting limited short-term excitement.
No financial performance data is available for analysis.
Analysts have mixed views. Baird raised its price target to $33 with an Outperform rating, while Wells Fargo downgraded the stock earlier. Stifel lowered its price target to $34 but maintains a Buy rating.
